MA49498A - Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant - Google Patents
Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenantInfo
- Publication number
- MA49498A MA49498A MA049498A MA49498A MA49498A MA 49498 A MA49498 A MA 49498A MA 049498 A MA049498 A MA 049498A MA 49498 A MA49498 A MA 49498A MA 49498 A MA49498 A MA 49498A
- Authority
- MA
- Morocco
- Prior art keywords
- diethylphenyl
- pyrazolo
- quinazoline
- carboxamide
- methoxyphenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305826 | 2017-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49498A true MA49498A (fr) | 2021-05-26 |
Family
ID=59313166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049498A MA49498A (fr) | 2017-06-29 | 2018-06-28 | Nouveau sel de n-(2,6-diéthylphényl)-8-((4-4-(diméthylamino)pipéridine-1-yl]-2-méthoxyphényl)amino)-1-méthyl-4,5-dihydro-1h-pyrazolo[4,3-h]quinazoline-3-carboxamide, sa préparation et formulations le contenant |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US11160806B2 (enExample) |
| EP (1) | EP3645535B1 (enExample) |
| JP (1) | JP7141416B2 (enExample) |
| KR (1) | KR102609333B1 (enExample) |
| CN (1) | CN110896636B (enExample) |
| AR (1) | AR112040A1 (enExample) |
| AU (1) | AU2018293729B9 (enExample) |
| CA (1) | CA3068357C (enExample) |
| CL (1) | CL2019003848A1 (enExample) |
| EA (1) | EA039764B1 (enExample) |
| ES (1) | ES2900048T3 (enExample) |
| IL (1) | IL271628B2 (enExample) |
| MA (1) | MA49498A (enExample) |
| PL (1) | PL3645535T3 (enExample) |
| PY (1) | PY1850855A (enExample) |
| SG (1) | SG11201912651WA (enExample) |
| TW (1) | TWI750393B (enExample) |
| UY (1) | UY37778A (enExample) |
| WO (1) | WO2019002454A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025002962A1 (en) | 2023-06-30 | 2025-01-02 | Nerviano Medical Sciences S.R.L. | Use of a mps1 inhibitor for the treatment of hepatocellular carcinoma |
| WO2025021587A1 (en) | 2023-07-21 | 2025-01-30 | Nerviano Medical Sciences S.R.L. | Combination of a mps1 inhibitor and immune checkpoint inhibitors, uses and pharmaceutical compositions thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0914649B1 (pt) * | 2008-06-26 | 2021-07-06 | Les Laboratoires Servier | Pirazolo-quinazolinas |
-
2018
- 2018-06-21 UY UY0001037778A patent/UY37778A/es not_active Application Discontinuation
- 2018-06-28 JP JP2019572116A patent/JP7141416B2/ja active Active
- 2018-06-28 ES ES18732820T patent/ES2900048T3/es active Active
- 2018-06-28 WO PCT/EP2018/067394 patent/WO2019002454A1/en not_active Ceased
- 2018-06-28 CA CA3068357A patent/CA3068357C/en active Active
- 2018-06-28 EP EP18732820.8A patent/EP3645535B1/en active Active
- 2018-06-28 AU AU2018293729A patent/AU2018293729B9/en active Active
- 2018-06-28 EA EA202090115A patent/EA039764B1/ru unknown
- 2018-06-28 TW TW107122235A patent/TWI750393B/zh active
- 2018-06-28 CN CN201880043442.0A patent/CN110896636B/zh active Active
- 2018-06-28 SG SG11201912651WA patent/SG11201912651WA/en unknown
- 2018-06-28 AR ARP180101781A patent/AR112040A1/es unknown
- 2018-06-28 PL PL18732820T patent/PL3645535T3/pl unknown
- 2018-06-28 PY PY201801850855A patent/PY1850855A/es unknown
- 2018-06-28 MA MA049498A patent/MA49498A/fr unknown
- 2018-06-28 US US16/624,488 patent/US11160806B2/en active Active
- 2018-06-28 KR KR1020207002339A patent/KR102609333B1/ko active Active
-
2019
- 2019-12-22 IL IL271628A patent/IL271628B2/en unknown
- 2019-12-26 CL CL2019003848A patent/CL2019003848A1/es unknown
-
2021
- 2021-09-30 US US17/490,318 patent/US20220016122A1/en not_active Abandoned
-
2024
- 2024-07-01 US US18/760,494 patent/US20240350501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2900048T3 (es) | 2022-03-15 |
| US11160806B2 (en) | 2021-11-02 |
| KR20200020905A (ko) | 2020-02-26 |
| IL271628B1 (en) | 2023-03-01 |
| AU2018293729B9 (en) | 2022-07-14 |
| UY37778A (es) | 2019-01-31 |
| US20220016122A1 (en) | 2022-01-20 |
| CN110896636A (zh) | 2020-03-20 |
| SG11201912651WA (en) | 2020-01-30 |
| EA202090115A1 (ru) | 2020-05-25 |
| KR102609333B1 (ko) | 2023-12-01 |
| EP3645535B1 (en) | 2021-09-08 |
| PY1850855A (es) | 2019-04-01 |
| TW201904971A (zh) | 2019-02-01 |
| US20240350501A1 (en) | 2024-10-24 |
| JP2020525477A (ja) | 2020-08-27 |
| CN110896636B (zh) | 2022-07-19 |
| EA039764B1 (ru) | 2022-03-11 |
| CL2019003848A1 (es) | 2020-07-10 |
| IL271628B2 (en) | 2023-07-01 |
| US20200246339A1 (en) | 2020-08-06 |
| EP3645535A1 (en) | 2020-05-06 |
| AU2018293729B2 (en) | 2022-03-10 |
| CA3068357A1 (en) | 2019-01-03 |
| WO2019002454A1 (en) | 2019-01-03 |
| PL3645535T3 (pl) | 2022-03-21 |
| TWI750393B (zh) | 2021-12-21 |
| AR112040A1 (es) | 2019-09-11 |
| CA3068357C (en) | 2022-04-19 |
| JP7141416B2 (ja) | 2022-09-22 |
| AU2018293729A1 (en) | 2020-01-23 |
| BR112019027924A2 (pt) | 2020-08-18 |
| IL271628A (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090659A1 (ru) | СОСТАВЫ, СОДЕРЖАЩИЕ 6-(2-ГИДРОКСИ-2-МЕТИЛПРОПОКСИ)-4-(6-(6-((6-МЕТОКСИПИРИДИН-3-ИЛ)МЕТИЛ)-3,6-ДИАЗАБИЦИКЛО[3.1.1]ГЕПТАН-3-ИЛ)ПИРИДИН-3-ИЛ)ПИРАЗОЛО[1,5-a]ПИРИДИН-3-КАРБОНИТРИЛ | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| EA201990519A1 (ru) | КРИСТАЛЛИЧЕСКАЯ ФОРМА (S)-7-(1-АКРИЛОИЛПИПЕРИДИН-4-ИЛ)-2-(4-ФЕНОКСИФЕНИЛ)-4,5,6,7-ТЕТРАГИДРОПИРАЗОЛО[1,5-a]ПИРИМИДИН-3-КАРБОКСАМИДА, ЕЕ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЯ | |
| EA201990657A1 (ru) | Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов | |
| MX2019003605A (es) | Formas solidas de un inhibidor de cdk4/6 selectivo. | |
| EA201891099A1 (ru) | 7-(тиазол-5-ил)пирролопиримида в качестве агониста рецептора tlr7 | |
| MX2018002017A (es) | Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina. | |
| WO2018045276A8 (en) | Fused bicyclic sgc stimulators | |
| PE20171307A1 (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| EA201591255A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) | |
| IL281924A (en) | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making | |
| HRP20201949T1 (hr) | 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji | |
| WO2014027975A3 (en) | Novel orally administered pharmaceutical formulations | |
| EP3250572A4 (en) | Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof | |
| PH12017500479A1 (en) | Liquid inhalation formulation comprising prl554 | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
| EA201591904A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK | |
| WO2016010869A3 (en) | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | |
| MX2019010756A (es) | Derivados novedosos de imidazo[4,5-c]quinolina como inhibidores de cinasa 2 rica en repetición de leucina (lrrk2). | |
| WO2014027981A3 (en) | Effervescent tablet formulations of dapoxetine and a pde5 inhibitor | |
| EA201690100A1 (ru) | Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин | |
| EA201790179A1 (ru) | [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний | |
| PH12014502407B1 (en) | New alfentanil composition for the treatment of acute pain | |
| IL271628A (en) | A new salt of N-(6,2-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl}amino)-1-methyl-5,4-dihydro-1H -pyrazolo[3,4-H]quinazoline-3-carboxamide, its preparation and formulations containing it |